我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

尾加压素II与血管重构(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2007年第5期
页码:
606-610
栏目:
综述
出版日期:
2007-10-01

文章信息/Info

Title:
Urotensin II and vascular remodeling
作者:
李军; 张勇刚; 李玉光
汕头大学医学院第一附属医院心内科，广东 汕头 515041
Author(s):
LI Jun;  ZHANG Yonggang;  LI Yuguang
Department of Cardiovascular Diseases, First Affiliated Hospital, Shantou University Medical College, Shantou 515041,Guang dong China
关键词:
尾加压素II; 血管重构; 信号转导
Keywords:
Urotensin II;  vascular remodeling;  signal transduction
分类号:
R543
DOI:
-
文献标识码:
A
摘要:
血管重塑与多种临床疾病有密切关系。尾加压素II是迄今为止在哺乳动物体内发现的最强的缩血管活性肽，参与了多种心血管疾病的病理生理过程，新近研究发现它在血管重塑过程中亦发挥着重要作用。
Abstract:
Urotensin II is one of the most potent vasoconstrictor known, even more potent than endothelin1. It was first isolated from the fish urophyses and has been recognized as a hormone in the neurosecretory system of teleost fish for over 30 years.After the identification of UII in humans and the orphan human Gproteincoupled receptor 14 (GPR14)as UII receptor(UT), many studies have shown that UII may play an important role in cardiovascular regulation. The present review suggess that UII may also bring into full play in vascular remodeling. In the text, we reviewed the physiological and pathophysiological significance of UII in the vasculature, and focused on the correlation between UII and vascular remodeling.

参考文献/References

［1］ 吴明,王安才.血管重构与临床［J］.心脏杂志, 2005，17(2):160-162,165.

［2］ Ashton N. Renal and vascular actions of urotensin II ［J］.Kidney Int, 2006, 70(4):624-629.

［3］ Carotenuto A, Grieco P, Rovero P,et al. UrotensinII receptor antagonists ［J］.Curr Med Chem, 2006, 13(3):267-275.

［4］ Grieco P, Carotenuto A, Campiglia P, et al. UrotensinII receptor ligands. From agonist to antagonist activity ［J］.J Med Chem, 2005, 48(23):7290-7297.

［5］ Lim M, Honisett S, Sparkes CD,et al. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure ［J］.Circulation, 2004, 109(10):1212-1214.

［6］ Zhu YZ, Wang ZJ, Zhu YC,et al. Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile［J］.Am J Physiol Heart Circ Physiol, 2004, 286(3): H830-H836.

［7］ Zhu YC, Zhu YZ, Moore PK. The role of urotensin II in cardiovascular and renal physiology and diseases［J］.Br J Pharmacol, 2006, 148(7):884-901.

［8］ Lacza Z, W Busija D. UrotensinII is a nitric oxidedependent vasodilator in the pial arteries of the newborn pig ［J］.Life Sci, 2006, 78(23):2763-2766.

［9］ Hassan GS, Douglas SA, Ohlstein EH,et al. Expression of urotensinII in human coronary atherosclerosis J］.Peptides, 2005, 26(12):2464-2472.

［10］Thanassoulis G, Huyhn T, Giaid A. Urotensin II and cardiovascular diseases［J］.Peptides, 2004, 25(10):1789-1794.

［11］Bousette N, Patel L, Douglas SA,et al. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta ［J］.Atherosclerosis, 2004, 176(1):117-123.

［12］王志坚，丁文惠，史力斌，等. apoE基因敲除小鼠主动脉尾加压素Ⅱ受体GPR14表达的变化［J］.中国病理生理杂志，2005, 21(11):2081-2085.

［13］ Rakowski E, Hassan GS, Dhanak D,et al. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker［J］.J Mol Cell Cardiol, 2005, 39(5):785-791.

［14］方石虎，李志樑，吴宏超，等. 冠心病患者血浆尾加压素Ⅱ的临床研究［J］，第一军医大学学报, 2004, 24(5):563-565.

［15］Wang H, Mehta JL, Chen K,et al. Human urotensin II modulates collagen synthesis and the expression of MMP1 in human endothelial cells ［J］.J Cardiovasc Pharmacol, 2004, 44(5):577-581.

［16］Shi L, Ding W, Li D,et al. Proliferation and antiapoptotic effects of human urotensin II on human endothelial cells ［J］.Atherosclerosis, 2006, 188(2):260-264.

［17］Matsushita M, Shichiri M, Fukai N,et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1 ［J］.Endocrinology, 2003, 144(5):1825-1831.

［18］Djordjevic T, BelAiba RS, Bonello S,et al. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells ［J］.Arterioscler Thromb Vasc Biol, 2005, 25(3):519-525.

［19］ Qi J, Du J, Tang X,et al. The upregulation of endothelial nitric oxide synthase and urotensinII is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting ［J］. Heart Vessels, 2004, 19(2):81-88.

［20］Tasaki K, Hori M, Ozaki H,et al. Mechanism of human urotensin IIinduced contraction in rat aorta ［J］.J Pharmacol Sci, 2004, 94(4):376-383.

［21］石向东,李志梁,吴宏超，等.尾加压素Ⅱ促血管内皮细胞分泌肾上腺髓质素的作用［J］.中华心血管病杂志, 2005, 33(9):836-839.

［22］Onan D, Pipolo L, Yang E,et al. Urotensin II promotes hypertrophy of cardiac myocytes via mitogenactivated protein kinases ［J］.Mol Endocrinol, 2004, 18(9):2344-2354.

备注/Memo

备注/Memo:
收稿日期：2006-09-28.Correspondence to: ZHANG Yonggang, associate professor, master supervisor. Direction: coronary heart disease.Email: zhangyg8686@hotmail.com.net.
更新日期/Last Update: